Starpharma Ltd., of Melbourne, Australia, submitted three of the five main modules for its NDA for Vivagel BV for the treatment and prevention of bacterial vaginosis through a rolling submission. The remaining modules are expected to be submitted in the near future. Starpharma is in the process of negotiating global and regional licensing deals for the drug.